Duality Biologics

Duality Biologics is an innovative clinical-stage biopharmaceutical company dedicated to discovering and developing next-generation Antibody-Drug Conjugate (ADC) therapeutics for patients with cancer and autoimmune diseases. With a focus on translating novel modalities into reality, Duality Biologics has successfully established several next-generation ADC technology platforms, secured with global intellectual property rights.

Based in Shanghai, CN, Duality Biologics leverages a deep understanding of disease biology and translational capabilities to advance innovative product candidates. Currently, Duality Biologics has four assets in global clinical studies and over ten innovative product candidates in the preclinical stage. The company continues to evolve its novel protein engineering and ADC technology platforms to create the next wave of "super ADC" molecules, including diverse payload classes, bispecific ADCs, and dual payload ADCs.

Duality Biologics is committed to becoming a world-leading ADC company. For more information, please visit www.dualitybiologics.com. We invite the management team at Duality Biologics to create a customized and exclusive company showcase and product listing on our platform to further highlight your groundbreaking work.